FDG positron emission tomography for the detection of ovarian cancer.
D054598:Blue Cross Blue Shield Insurance Plans; D017277:Drug Approval; D005260:Female; D005434:Flow Cytometry; D005462:Fluorine Radioisotopes; D019788:Fluorodeoxyglucose F18; D005500:Follow-Up Studies; D006801:Humans; D019458:Insurance Coverage; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging; D017063:Outcome Assessment, Health Care; D010051:Ovarian Neoplasms / Q000000981:diagnostic imaging*; D019275:Radiopharmaceuticals; D013673:Technology Assessment, Biomedical; D014055:Tomography, Emission-Computed; D014481:United States
D005462:Fluorine Radioisotopes; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18